1st Quarter 2023 Results

Joaquin Duato
Chairman of the Board &
Chief Executive Officer
Johnson & Johnson

“Our first quarter results demonstrate strong performance across all three segments of our business and reflect the dedication of Johnson & Johnson colleagues around the world. With this momentum, I look forward to the remainder of the year, one filled with exciting catalysts that will create both near- and long-term value for patients and all of our stakeholders.”


*Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

**Basic shares are used to calculate loss per share as use of diluted shares when in a loss position would be anti-dilutive.

/one.numrNon-GAAP measure; excludes the impact of translational currency.

Caution Concerning Forward-Looking Statements: This document contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance. You are cautioned not to rely on these forward-looking statements, which are based on current expectations of future events. For important information about the risks and uncertainties that could cause actual results to vary materially from the assumptions, expectations, and projections expressed in any forward-looking statements, review the “Note to Investors Concerning Forward-Looking Statements” included in the Johnson & Johnson earnings release issued on April 18, 2023 as well as the most recently filed Johnson & Johnson Reports on Forms 10-K and 10-Q. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

1st Quarter 2023 Sales

Worldwide $24.7B 5.6%
Excluding acquisitions/divestitures on an operational basis
Worldwide $24.7B 7.6%

Basic Loss Per Share** $(0.03) Decreased (101.6)%
Adjusted Diluted Earnings Per Share* $2.68 Increased 0.4%

Worldwide Consumer Health Sales
Consumer Health worldwide reported sales increased 7.4% or 11.3% operationally. Primary operational drivers:

Neutrogena
Motrin
Aveeno

Worldwide Pharmaceutical Sales
Pharmaceutical worldwide reported sales increased 4.2% or 7.2% operationally. Primary operational drivers:

DARALEX
Xarelto
Spravato

Worldwide MedTech Sales
MedTech worldwide reported sales increased 7.3% or 11.0% operationally. Primary operational drivers:

Biosurgery
Trauma

Note: values may have been rounded.


*Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

**Basic shares are used to calculate loss per share as use of diluted shares when in a loss position would be anti-dilutive.

/one.numrNon-GAAP measure; excludes the impact of translational currency.